(S (SBAR (IN Although) (S (NP (PRP he)) (VP (AUX has) (RB not) (ADVP (RB yet)) (VP (VBN broken) (NP (NP (DT the) (NN research) (NN code)) (VP (TO to) (VP (VB see) (SBAR (SBAR (WHNP (WP who)) (VP (AUX is) (VP (VBG getting) (NP (JJ active) (NN medication))))) (CC and) (SBAR (WHNP (WP who)) (VP (VBZ is) (PP (IN on) (NP (DT a) (JJ look-alike) (NN placebo))))))))))))) (, ,) (NP (PRP he)) (VP (VBD said) (S (NP (NP (DT the) (VBG quitting) (NN rate)) (PP (IN at) (NP (CD 12) (NNS weeks)))) (VP (VBD was) (NP (NP (QP (JJR more) (IN than) (RB twice)) (IN that)) (VP (VBN seen) (PP (IN in) (NP (NP (JJ previous) (NN placebo) (NNS studies)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB strongly)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT the) (NN drug)) (VP (AUX is) (VP (VBG working))))))))))))))))) (. .))
